Abstract
ABO incompatible renal transplantation has gained wide spread acceptance in view of organ shortage. Acceptable Anti A and Anti B titres are achieved by various preconditioning regimens. Some patients have difficulty in achieving target titres due to refractory and rebound isoagglutinin titres. We share our experience with the use of Bortezomib in patients having moderately high base line isoagglutinin titres who had difficulty in achieving target titres during the preconditioning treatment. The use of Bortezomib can possibly reduce the number of plasma exchanges and its attendant complications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical Reviews and Case Reports
Paper Title
Journal
Date
